Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 90 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Antihypertensive Agents Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study of the Impact of the Patient Activated Learning System (PALS) on Knowledge Acquisition, Recall, and Decision Making

NCT03156634
View directory record Official record
Conditions
Patient Education
Interventions
PALS, WebMD
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Not applicable Interventional

A ED-based Intervention to Improve Antihypertensive Adherence

NCT02672787
View directory record Official record
Conditions
Hypertensive Emergency, Hypertension, Blood Pressure
Interventions
ED-based behavioral intervention, ED usual care plus education
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Not applicable Interventional Results available

The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

NCT00716079
View directory record Official record
Conditions
Intracerebral Hemorrhage, Stroke, Hypertension
Interventions
Blood pressure management policies
Other
Lead sponsor
The George Institute
Other
Eligibility
18 Years and older
Enrollment
2,839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Phase 3 Interventional

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

NCT00330369
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 5, 2026, 5:56 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Intensive Postpartum Antihypertensive Treatment

NCT05687344
View directory record Official record
Conditions
Hypertensive Disorder of Pregnancy
Interventions
Nifedipine ER
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 5, 2026, 5:56 PM EDT
Withdrawn No phase listed Observational

Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs

NCT00573092
View directory record Official record
Conditions
Myocardial Infarction, Cerebrovascular Accident, Death, Sudden, Cardiac
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Oct 5, 2026, 5:56 PM EDT
Not yet recruiting Phase 3 Interventional

Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)

NCT07083765
View directory record Official record
Conditions
Hypertension, Hypertension,Essential
Interventions
Dehydrated Alcohol Injection, USP, Sham procedure
Drug · Procedure
Lead sponsor
Ablative Solutions, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

NCT00758524
View directory record Official record
Conditions
Essential Hypertension
Interventions
LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 5, 2026, 5:56 PM EDT
Terminated Phase 2 Interventional Results available

Field Administration of Stroke Therapy-Blood Pressure Lowering

NCT01811693
View directory record Official record
Conditions
Intracerebral Hemorrhage, Ischemic Stroke
Interventions
Glycerly Trinitrate
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Los Alamitos, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

NCT05769608
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
104
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Not applicable Interventional Results available

Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

NCT02412761
View directory record Official record
Conditions
Essential Hypertension
Interventions
Lisinopril, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Years to 22 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 5, 2026, 5:56 PM EDT
Recruiting Not applicable Interventional

Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension

NCT06526858
View directory record Official record
Conditions
Resistant Hypertension
Interventions
HyperQureTM Renal Denervation (RDN) System:
Device
Lead sponsor
DeepQure Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Orange, California • Stanford, California • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life

NCT00999102
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol, Nebivolol
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

NCT01953432
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 5, 2026, 5:56 PM EDT
Not listed Not applicable Interventional

Evaluation of a Decision Support Tool

NCT02060981
View directory record Official record
Conditions
Medication Adherence, Hypertension, Decision Making, Shared, Patient-Centered Outcomes Research
Interventions
Control, Interview Only, Interview plus decision support tool
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 5, 2026, 5:56 PM EDT
Recruiting Not applicable Interventional

The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.

NCT05676476
View directory record Official record
Conditions
Preeclampsia, Gestational Hypertension, Hypertensive Disorder of Pregnancy
Interventions
Antihypertensive treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 49 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Oct 5, 2026, 5:56 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Preventing Sickle Cell Kidney Disease

NCT02373241
View directory record Official record
Conditions
Anemia, Sickle Cell, Sickle Cell Disease, Kidney Disease, Hypertension, Proteinuria
Interventions
Losartan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 5, 2026, 5:56 PM EDT
Terminated Phase 3 Interventional Results available

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

NCT03657095
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Esuberaprost, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 5, 2026, 5:56 PM EDT
Terminated Phase 3 Interventional Results available

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

NCT01176565
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Intravenous nicardipine hydrochloride
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
116
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 5, 2026, 5:56 PM EDT
Completed No phase listed Observational Results available

Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock

NCT02884011
View directory record Official record
Conditions
Septic Shock
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Phase 4 Interventional

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

NCT04412096
View directory record Official record
Conditions
Glaucoma, OHT - Ocular Hypertension
Interventions
Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 5, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain

NCT03396588
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine, Morphine
Drug
Lead sponsor
Henrietta Bada
Other
Eligibility
12 Hours to 7 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 5, 2026, 5:56 PM EDT